博济医药：拟集中竞价减持不超266.7万股回购股份

Group 1 - The company announced that its board of directors approved a share repurchase plan to maintain company value and shareholder rights, intending to reduce up to 2,667,000 shares, which represents 0.69% of the total share capital [1] - The reduction period is set from March 19, 2026, to September 18, 2026, with the price determined by the secondary market [1] - In 2024, the company repurchased a total of 2,667,000 shares for a total transaction amount of 15.0968 million yuan [1] Group 2 - The proceeds from the share reduction will be used to supplement working capital, and this reduction will not lead to changes in control or total share capital [1] - The controlling shareholder and its concerted parties had previously reduced their holdings by a total of 11,486,500 shares from September to December 2025 [1]